title: Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.
abstract: Gastrointestinal and vaginal mucosa are major sites of entry in natural HIV infection and therefore the preferred sites to elicit high-avidity CD8+ CTL by vaccination. We directly compare systemic and mucosal immunization in mice after DNA priming and boosting with rgp160 env expressed either in MVA or Ad for their ability to induce mucosal as well as systemic HIV-specific CTL. The optimal CTL response in the gut mucosa was observed after priming with the HIV-1 gp160 env DNA vaccine and boosting with rMVA or rAd encoding the same envelope gene all administered intrarectally (IR). Maximum levels of high-avidity CD8+ T cells were seen in intestinal lamina propria following this regimen. When the prime and boost routes were distinct, the delivery site of the boost had a greater impact than the DNA priming. IM DNA prime and IR rMVA boost were more effective than IR DNA prime and IM rMVA boost for eliciting mucosal CD8+ T-cell avidity. A systemic DNA-prime-followed by systemic rMVA boost induced high levels of high-avidity CD8+ T cells systemically, but responses were undetectable in mucosal sites. A single systemic immunization with rMVA was sufficient to induce high-avidity IFN-gamma secreting CD8+ T cells in systemic organs, whereas a single mucosal immunization with rMVA was not sufficient to elicit high-avidity CD8+ T cells in mucosa. Thus, a heterologous mucosal DNA prime-viral vectored boost strategy was needed. The requirement for a heterologous DNA prime-recombinant viral boost strategy for generation of high-avidity CD8+ T cells in mucosal sites in mice may be more stringent than for the induction of high-avidity CD8+ T cells in systemic compartments.
authors.affiliation: Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA; Midwest Research Institute, Frederick, MD 21702, USA. igorbelyakov@yahoo.com
authors.forename: Igor M
authors.initials: IM
authors.lastname: Belyakov
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Ahlers
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: Bernard
authors.initials: B
authors.lastname: Moss
authors.forename: Jay A
authors.initials: JA
authors.lastname: Berzofsky
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D003602:Cytotoxicity, Immunologic; D005260:Female; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D007413:Intestinal Mucosa / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D019444:Vaccines, DNA
references.citation: Methods Mol Med. 2006;127:171-97
references.pmid: 16988455
references.citation: Science. 2001 Apr 6;292(5514):69-74
references.pmid: 11393868
references.citation: Health Aff (Millwood). 2007 Jul-Aug;26(4):1147-58
references.pmid: 17630459
references.citation: J Virol. 2003 Feb;77(4):2400-9
references.pmid: 12551977
references.citation: J Exp Med. 2000 Jul 3;192(1):63-75
references.pmid: 10880527
references.citation: J Virol. 2004 Jul;78(14):7490-7
references.pmid: 15220422
references.citation: J Immunol. 2006 Nov 1;177(9):6336-43
references.pmid: 17056564
references.citation: J Immunol. 2003 Sep 1;171(5):2538-47
references.pmid: 12928404
references.citation: J Clin Invest. 2001 Dec;108(11):1677-85
references.pmid: 11733563
references.citation: J Virol. 2001 Dec;75(23):11483-95
references.pmid: 11689630
references.citation: J Immunol. 2002 Jan 1;168(1):332-7
references.pmid: 11751978
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7
references.pmid: 10759543
references.citation: J Immunol. 2001 Dec 15;167(12):7180-91
references.pmid: 11739541
references.citation: Nature. 2002 Jan 17;415(6869):331-5
references.pmid: 11797011
references.citation: J Immunol. 2000 May 1;164(9):4968-78
references.pmid: 10779808
references.citation: Immunol Rev. 2007 Feb;215:226-42
references.pmid: 17291292
references.citation: Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1709-14
references.pmid: 9465081
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
references.pmid: 8633023
references.citation: Immunity. 2004 Mar;20(3):247-53
references.pmid: 15030769
references.citation: J Immunol. 2000 Dec 1;165(11):6454-62
references.pmid: 11086085
references.citation: Virology. 2008 Mar 15;372(2):260-72
references.pmid: 18048074
references.citation: Blood. 2006 Apr 15;107(8):3258-64
references.pmid: 16373659
references.citation: Nat Med. 2000 Feb;6(2):200-6
references.pmid: 10655110
references.citation: Nat Med. 2001 Dec;7(12):1320-6
references.pmid: 11726972
references.citation: Int Immunol. 2002 Jan;14(1):31-7
references.pmid: 11751749
references.citation: Infect Immun. 1997 Apr;65(4):1387-94
references.pmid: 9119478
references.citation: J Immunol. 2006 Jul 15;177(2):831-9
references.pmid: 16818737
references.citation: Curr Mol Med. 2003 May;3(3):285-301
references.pmid: 12699364
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7
references.pmid: 10200293
references.citation: Science. 1999 Nov 12;286(5443):1353-7
references.pmid: 10558989
references.citation: Immunity. 2004 Oct;21(4):527-38
references.pmid: 15485630
references.citation: J Clin Invest. 1998 Dec 15;102(12):2072-81
references.pmid: 9854042
references.citation: J Clin Invest. 2004 Aug;114(4):450-62
references.pmid: 15314679
references.citation: J Virol. 2003 Jun;77(12):7048-57
references.pmid: 12768024
references.citation: J Med Primatol. 2002 Aug;31(4-5):217-27
references.pmid: 12390544
references.citation: J Virol. 1989 Oct;63(10):4277-84
references.pmid: 2778875
references.citation: Vaccine. 2002 Jan 31;20(9-10):1295-307
references.pmid: 11818148
references.citation: J Exp Med. 2004 Sep 20;200(6):749-59
references.pmid: 15365096
references.citation: Nature. 2005 Apr 28;434(7037):1093-7
references.pmid: 15793563
references.citation: Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9
references.pmid: 2452443
references.citation: J Virol. 2001 May;75(10):4947-51
references.pmid: 11312370
references.citation: J Clin Virol. 2004 Dec;31 Suppl 1:S69-82
references.pmid: 15567097
references.citation: Virology. 2006 Oct 25;354(2):299-315
references.pmid: 16904153
references.citation: J Clin Invest. 2004 Apr;113(7):998-1007
references.pmid: 15057306
references.citation: Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S65-73
references.pmid: 15285706
references.citation: J Virol. 2003 Jun;77(11):6305-13
references.pmid: 12743287
references.citation: J Immunol. 2006 May 1;176(9):5338-45
references.pmid: 16622001
references.citation: J Virol. 1998 Dec;72(12):10180-8
references.pmid: 9811759
references.citation: J Virol. 2003 Nov;77(21):11708-17
references.pmid: 14557656
references.citation: Immunol Rev. 1999 Aug;170:151-72
references.pmid: 10566149
references.citation: Vaccine. 1998 Mar;16(5):439-45
references.pmid: 9491498
references.citation: J Immunol. 1999 Jan 15;162(2):989-94
references.pmid: 9916724
references.citation: J Virol. 2002 Jun;76(11):5357-68
references.pmid: 11991964
references.citation: Curr HIV Res. 2003 Jul;1(3):287-94
references.pmid: 15046253
references.citation: J Gene Med. 2003 Jan;5(1):3-10
references.pmid: 12516046
references.citation: Virology. 2007 Oct 10;367(1):156-67
references.pmid: 17590405
references.citation: AIDS. 1998 Dec 24;12(18):2407-15
references.pmid: 9875578
references.citation: Virology. 2003 Aug 15;313(1):13-21
references.pmid: 12951017
references.citation: J Exp Med. 2006 May 15;203(5):1249-58
references.pmid: 16636134
references.citation: Vaccine. 2007 Mar 8;25(12):2187-93
references.pmid: 17229501
references.citation: J Exp Med. 1996 Jan 1;183(1):215-25
references.pmid: 8551225
references.citation: J Immunol. 2000 Feb 1;164(3):1602-11
references.pmid: 10640781
references.citation: J Immunol. 1999 Feb 15;162(4):2227-34
references.pmid: 9973498
references.citation: J Clin Invest. 2004 Jun;113(11):1515-25
references.pmid: 15173875
references.citation: J Immunol. 2007 Sep 15;179(6):3504-14
references.pmid: 17785784
references.citation: J Virol. 2006 Apr;80(8):3732-42
references.pmid: 16571790
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63
references.pmid: 12869693
references.citation: Science. 1998 Apr 17;280(5362):427-31
references.pmid: 9545219
references.citation: J Virol. 1998 Oct;72(10):8264-72
references.pmid: 9733870
references.citation: J Exp Med. 1998 May 18;187(10):1647-57
references.pmid: 9584143
references.citation: J Immunol. 2001 Feb 1;166(3):1690-7
references.pmid: 11160212
references.citation: Science. 2002 Jun 28;296(5577):2335
references.pmid: 12090274
references.citation: J Immunol. 2007 Feb 15;178(4):2370-9
references.pmid: 17277143
references.citation: J Exp Med. 2004 Sep 20;200(6):761-70
references.pmid: 15365095
references.citation: J Immunol. 2007 Jun 1;178(11):7211-21
references.pmid: 17513770
references.citation: Int Immunol. 2007 Dec;19(12):1413-20
references.pmid: 17981793
references.citation: Eur J Immunol. 2001 Dec;31(12):3557-66
references.pmid: 11745375